Oncology & Cancer

Receptor structure reveals new targets for cancer treatment

A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule—its role in the ...

Oncology & Cancer

Scientists discover a key genetic driver of lymphomas

Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller ...

Oncology & Cancer

Researchers characterize mechanism of action of CAR T cells

The scientific community has made great strides over the past decade in the development of a new class of cancer therapy called immunotherapy, a treatment that activates a patient's own immune system to target cancer cells. ...

Oncology & Cancer

Immune-engineered device targets chemo-resistant lymphoma

Non-Hodgkin lymphoma, a cancer that is diagnosed in the U.S. more than 70,000 times annually, arises from overly proliferating immune cells within the body's lymph nodes, which are connected to a network of lymph vessels ...

Oncology & Cancer

DNA sequencing determines lymphoma origin, prognosis

Sequencing tiny bits of DNA circulating in the blood of patients with lymphoma can accurately identify the cancer subtype and pinpoint mutations that might cause drug resistance, according to researchers at the Stanford University ...

page 2 from 13